Trial of Erenumab for Preventive Treatment of Pediatric migraine 15 days per month or more

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

8 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine 15 days per month or more. Eligible participants will be given either erenumab or placebo, assigned randomly (like the flip of a coin), followed by an open-label phase in which all participants receive erenumab. Erenumab has been FDA-approved for use in adults to decrease the frequency of migraine. Patients may be eligible to participate if they have had migraine for at least one year, and agree to come to CHOP's main hospital for several study visits. Patients whose headache started suddenly (New Daily Persistent Headache), patients whose headache started after a concussion (Post-Traumatic Headache), and patients with severe depression are not eligible for this study.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at headacheprogram [at] chop.edu or 267-602-9784.

Eligibility & Criteria

IRB #:
19-016401
Official Title:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine
Study Phase:
Phase III
Eligible Age Range:
6 - 17 Years
Gender:
All
Study Categories:

Leader

Christina Szperka, MD, MSCE